Recent 8-K filings for BIXT

• March 13, 2026, 7:59 PM ET other material materiality 0.70 neutral item 3.03item 5.02item 5.03item 9.01 ◈ Governance Changes

  Bioxytran amends preferred stock conversion rights, grants CEO 6M preferred shares

  Amendment requires both Board and majority of Preferred holders to approve any conversion of Convertible Preferred Stock into common shares.

• March 2, 2026, 6:59 PM ET other material materiality 0.80 positive item 8.01item 9.01

  Bioxytran's ProLectin-M achieves 90% Day-5 viral clearance in Phase 1b/2a COVID-19 study

  Phase 1b/2a trial: 39 patients; highest dose 16,800 mg/day showed 90% Day-5 viral clearance vs 20% placebo (p=0.001).

• February 11, 2026, 6:59 PM ET other material materiality 0.85 positive item 8.01item 9.01

  Bioxytran reports Phase 2 ProLectin-M shows 100% viral clearance at day 7; p=0.001

  100% of treated subjects achieved complete viral clearance by Day 7 vs placebo (p=.001).

• April 3, 2025, 7:59 PM ET M&A materiality 0.60 neutral item 1.01item 7.01item 9.01

  Bioxytran acquires NDPD Pharma in $15.85M stock deal; CFO adopts 10b5-1 plan

  Acquired 100% of NDPD Pharma for 3,389,169 common shares and 28,467,564 preferred shares valued at ~$12.46M.

• January 22, 2025, 6:59 PM ET other material materiality 0.75 positive item 1.01item 8.01item 3.02item 9.01

  Bioxytran secures $1.6M stock purchase with Triton Funds; management forfeits $460K salaries

  Triton Funds LP commits up to $1.6M for up to 17.5M shares (19.9%) at lowest traded price 10 days prior to closing.

• January 13, 2025, 6:59 PM ET other material materiality 0.80 negative item 4.02item 9.01 ◈ Auditor Changes

  BioXytran restates 2022-2023 financials on share valuation errors; non-reliance on prior filings

  Net loss for 2023 increased by $192,523 to $4.56M; for 2022 increased by $9,202 to $2.67M.

• October 29, 2024, 7:59 PM ET M&A materiality 0.60 neutral item 1.01item 7.01item 9.01

  Bioxytran acquires NDPD Pharma for $15.85M in stock; CFO adopts 10b5-1 plan

  Acquired 100% of NDPD Pharma for stock: 3.39M common shares at $0.109 and 28.47M preferred shares at $0.543.

• August 20, 2024, 7:59 PM ET other material materiality 0.75 neutral item 3.03item 8.01item 9.01

  Bioxytran issues 28.97M preferred shares to insiders, converts 94M common shares and $354K debt

  Issued 28,971,248 convertible preferred shares to insiders in exchange for 94,057,658 common shares at a 5:1 ratio.

• July 17, 2024, 7:59 PM ET other material materiality 0.70 positive item 1.01item 8.01item 9.01

  Bioxytran launches JV with Heme Foundation for universal oxygen carrier; up to $10M pledged

  JV with Heme Foundation and NDPD Pharma to develop Universal Oxygen Carrier (UOC) as blood substitute.

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event other_material

6 positive 3 negative 7 neutral

source · BIXT on sec.gov